Samsung Biologics Expands U.S. Manufacturing Capabilities with Strategic Acquisition of Human Genome Sciences from GSK
PR Newswire —
Secures the company's first U.S.-based manufacturing site, strengthening and diversifying its global supply network Additional investments planned to expand the site's capacity (currently at 60,000 liters of drug substance) and capabilities to support growing manufacturing programs...